# Eliana RD — AI Index

Eliana Witchell is a Registered Dietitian and Certified Diabetes Educator specializing in metabolic health nutrition and GLP-1 medication nutrition support. Within licensed jurisdictions (Ontario, British Columbia, Nova Scotia in Canada) she offers individualized Medical Nutrition Therapy. Outside those jurisdictions the public-facing content on this site is educational only and does not constitute a patient-dietitian relationship.

Last updated: 2026-04-17.

## Reviewer

- Name: Eliana Witchell
- Credentials: MSc (Nutrition), RD (Registered Dietitian), CDE (Certified Diabetes Educator)
- Practice: Eliana RD (ElianaRD.com)
- Specializations: metabolic health, type 2 diabetes, prediabetes, PCOS, metabolic syndrome, GLP-1 medication nutrition support, therapeutic carbohydrate restriction

## Site model

Public front doors serve patients and healthcare professionals. Condition hubs and scenario hubs are the canonical educational surfaces. Case studies are the proof layer. Tools and resources are hub-owned.

## Front doors

- https://www.elianard.com/patients — Patient front door and entry point to the free Initial Consult Experience
- https://www.elianard.com/healthcare-professionals — Provider referral and collaborative-care workflow (Ontario, British Columbia, Nova Scotia)

## GLP-1 Nutrition scenario hub

- https://www.elianard.com/glp-1-nutrition — Canonical hub for GLP-1 medication nutrition support covering Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus

## GLP-1 canonical answer pages — Phase 1 (candidacy, safety, first-wave framework)

- https://www.elianard.com/glp-1-nutrition/is-this-for-me — Honest candidacy framing
- https://www.elianard.com/glp-1-nutrition/mental-health-considerations — Patient-safety framing, psychiatric symptom prevalence, psychosocial support
- https://www.elianard.com/glp-1-nutrition/muscle-loss — The central long-term risk; protein and resistance-training minimums
- https://www.elianard.com/glp-1-nutrition/protein-requirements — 1.6 g/kg ideal body weight per day, 30 g per meal floor, daily target by height
- https://www.elianard.com/glp-1-nutrition/what-to-eat — Appetite-led meal framework, morning-nausea strategy
- https://www.elianard.com/glp-1-nutrition/nausea — Most common GLP-1 side effect, management playbook, red-flag list
- https://www.elianard.com/glp-1-nutrition/fatigue — Second most reported symptom; three most common drivers; self-audit framework
- https://www.elianard.com/glp-1-nutrition/protein-calculator — Interactive daily protein target calculator

## GLP-1 canonical answer pages — Phase 2 (symptom depth, medications, delivery route)

- https://www.elianard.com/glp-1-nutrition/not-hungry — Eat on schedule, not by hunger; minimum-day framework
- https://www.elianard.com/glp-1-nutrition/meal-plan — One-week example meal pattern with substitutions
- https://www.elianard.com/glp-1-nutrition/acid-reflux-and-sulfur-burps — Slowed gastric emptying mechanism; trigger foods; positional and timing fixes
- https://www.elianard.com/glp-1-nutrition/food-aversions — Why taste and tolerance shift; work-with-not-against strategy
- https://www.elianard.com/glp-1-nutrition/hair-loss — Telogen effluvium framing; nutritional drivers; expected timeline
- https://www.elianard.com/glp-1-nutrition/stress-sleep-and-why-it-may-not-work — Diagnostic audit when the medication is not the problem
- https://www.elianard.com/glp-1-nutrition/dosing-and-titration — Four response patterns; decision points; philosophy split
- https://www.elianard.com/glp-1-nutrition/ozempic — Semaglutide for type 2 diabetes; hypoglycemia on concurrent insulin or sulfonylurea
- https://www.elianard.com/glp-1-nutrition/wegovy — Semaglutide for chronic weight management; muscle preservation framework
- https://www.elianard.com/glp-1-nutrition/mounjaro — Tirzepatide for type 2 diabetes; dual GIP + GLP-1 mechanism
- https://www.elianard.com/glp-1-nutrition/zepbound — Tirzepatide for chronic weight management
- https://www.elianard.com/glp-1-nutrition/saxenda — Liraglutide; older daily injectable; the 9-month plateau pattern
- https://www.elianard.com/glp-1-nutrition/rybelsus — Oral semaglutide; critical 30-minute empty-stomach absorption window
- https://www.elianard.com/glp-1-nutrition/oral-vs-injectable — Comparison of routes, cold-chain constraints, patient profiles
- https://www.elianard.com/glp-1-nutrition/next-generation-oral-glp1 — Pipeline awareness for orforglipron and other non-peptide small-molecule oral candidates

## GLP-1 canonical answer pages — Phase 3 (support, economics, tools, underreported signals)

- https://www.elianard.com/glp-1-nutrition/coming-off-glp-1 — Managed-transition framework; 90-day post-discontinuation plan
- https://www.elianard.com/glp-1-nutrition/exercise-and-muscle-preservation — Scope-honest minimum resistance-training dose and referral pathways
- https://www.elianard.com/glp-1-nutrition/labs-and-monitoring — Recommended baseline and ongoing blood work; pattern interpretation
- https://www.elianard.com/glp-1-nutrition/gaunt-face-and-hanging-skin — Pace + protein + training; realistic skin-reabsorption expectations
- https://www.elianard.com/glp-1-nutrition/cost-and-access — Out-of-pocket cost; one-year commitment rule; savings card mechanics
- https://www.elianard.com/glp-1-nutrition/insurance-and-coverage — Canadian and US coverage reference points
- https://www.elianard.com/glp-1-nutrition/quick-start-guide — First-30-days preparation and early-treatment checklist
- https://www.elianard.com/glp-1-nutrition/meal-ideas — Practical idea bank by appetite window and tolerance
- https://www.elianard.com/glp-1-nutrition/side-effect-tracker — Structured tracker template with example rows
- https://www.elianard.com/glp-1-nutrition/menstrual-and-reproductive-effects — Self-reported menstrual irregularities; hypothesized mechanisms; pregnancy considerations

## GLP-1 canonical answer pages — Phase 4 (condition crossover, program)

- https://www.elianard.com/glp-1-nutrition/diabetes — GLP-1 + SGLT2 + metformin stack; hypoglycemia precautions; carbohydrate planning
- https://www.elianard.com/glp-1-nutrition/pcos — Insulin-resistance framework; fertility planning and contraception
- https://www.elianard.com/glp-1-nutrition/metabolic-syndrome — Multi-system care; dyslipidemia, hypertension, insulin resistance, NAFLD
- https://www.elianard.com/glp-1-nutrition/post-cardiac-event — Medication-stack picture; fatigue-misattribution problem; cardiac rehab coordination
- https://www.elianard.com/glp-1-nutrition/program — Three layers of support: free Experience, course and community, individualized MNT

## GLP-1 proof layer

- https://www.elianard.com/case-studies/glp1-weight-loss-muscle-preservation — Clinical case study: female, early 40s on Wegovy (semaglutide 2.4 mg) achieved 35 lb weight loss with lean muscle mass maintained within 2% of baseline on DEXA

## Case studies

- https://www.elianard.com/case-studies — Index of all case studies
- https://www.elianard.com/case-studies/type-2-diabetes-cardiovascular-recovery — Type 2 diabetes + cardiovascular recovery
- https://www.elianard.com/case-studies/metabolic-syndrome-reversal — Metabolic syndrome
- https://www.elianard.com/case-studies/prediabetes-reversal — Prediabetes
- https://www.elianard.com/case-studies/dyslipidemia-statin-refractory — Dyslipidemia, statin-refractory
- https://www.elianard.com/case-studies/hypothyroid-autoimmune-fatigue — Hypothyroid + autoimmune fatigue
- https://www.elianard.com/case-studies/obesity-mental-health-sleep-recovery — Obesity + mental health + sleep recovery

## Compliance framing

Every page on this site is framed as educational content. Condition-specific and medication-specific pages state that the content does not replace individualized Medical Nutrition Therapy or medical care. Individualized MNT is offered only in jurisdictions where Eliana Witchell holds active licensure (Ontario, British Columbia, Nova Scotia).

## Evidence Library (canonical source)

The Clinical Evidence Library at /evidence is the canonical source for every evidence-backed claim on this site. Entries are atomic, graded, and reviewed; cluster pages cite upstream into this tree. Organized by seven clinical domains; a single entry has one primary domain and may be cross-filed into additional secondary domains.

- https://www.elianard.com/evidence — Root index of all published entries across seven domains
- https://www.elianard.com/evidence/mechanism — Mechanism & Pharmacology domain
- https://www.elianard.com/evidence/efficacy — Clinical Efficacy domain
- https://www.elianard.com/evidence/safety — Safety & Tolerability domain
- https://www.elianard.com/evidence/nutrition — Nutrition Science domain
- https://www.elianard.com/evidence/special-populations — Special Populations domain
- https://www.elianard.com/evidence/discontinuation — Discontinuation & Long-term Management domain
- https://www.elianard.com/evidence/emerging-agents — Emerging Agents domain
- https://www.elianard.com/glp-1-nutrition/evidence — Hub-scoped index of evidence entries that feed the GLP-1 Nutrition cluster

### Published entries

- https://www.elianard.com/evidence/nutrition/protein-1-6-g-kg-glp1 — Daily protein target of 1.6 g/kg ideal body weight for patients on GLP-1 medications. Grade B. Anchor for the /protein-requirements cluster page.
- https://www.elianard.com/evidence/nutrition/mps-leucine-threshold — Per-meal protein threshold for muscle protein synthesis: the 30 g / leucine-trigger rule. Grade B.
- https://www.elianard.com/evidence/nutrition/nitrogen-balance-rda-limitations — Why the 0.8 g/kg protein RDA systematically underestimates true requirements. Grade A (methodological consensus).
- https://www.elianard.com/evidence/special-populations/anabolic-resistance-aging — Anabolic resistance in aging and the elevated protein requirement for older adults. Grade B.
- https://www.elianard.com/evidence/safety/statin-induced-t2d-risk — Statin-induced risk of new-onset type 2 diabetes: magnitude, mechanism, and clinical implications. Grade A.

## Evidence base

Public educational pages cite peer-reviewed research through the Evidence Library. Real-world patient-reported data draws on Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026. DOI: 10.1038/s44360-026-00108-y. Clinical-trial references include Wilding et al. 2021 (STEP 1, DOI: 10.1056/NEJMoa2032183) and Jastreboff et al. 2022 (SURMOUNT-1, DOI: 10.1056/NEJMoa2206038). Protein requirements anchor on Layman et al. 2015 (Am J Clin Nutr. 101(6):1330S-1338S) and the broader literature synthesized at https://www.elianard.com/evidence/nutrition/protein-1-6-g-kg-glp1.

## Contact

Provider referrals and collaborative-care workflow: https://www.elianard.com/healthcare-professionals